The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day ...
In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive ...
In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures ...
A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...
In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while ...
The Inflation Reduction Act (IRA) of 2022 introduced sweeping changes to the US prescription drug market, most notably ...
CMS’s CY 2027 Medicare Advantage rates signal mounting cost pressure, setting the stage for tighter benefits, tougher contracting, and heightened access scrutiny in the months ahead.
A conservative 3% trend means a $100 billion Medicare Advantage book could face a $3 billion shortfall. Even before the Final ...
In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences moves to acquires Arcellx in a massive expansion of its cell therapy ...
Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results